BioCentury
ARTICLE | Translation in Brief

PET projects

Biogen and AC Immune collaborate to develop PET reagents for PD and ALS

May 12, 2016 7:00 AM UTC

Recent high-profile failures in clinical trials for Alzheimer's disease (AD) have underscored the role that imaging agents could play in identifying the right trial populations and tracking their responses. AC Immune S.A. and Biogen Inc. (NASDAQ:BIIB) are taking the learnings into other neurodegenerative diseases with a collaboration to develop PET imaging agents for Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), using AC Immune's Morphomer chemistry platform.

AC Immune CEO Andrea Pfeifer told BioCentury, "Today, diagnostics are almost a prerequisite in the neurodegenerative disease space to do the proper clinical trials, to identify the right patients."...